2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14257
    BMS-191095 hydrochloride 166095-95-0 98%
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.
    BMS-191095 hydrochloride
  • HY-14753
    Rosonabant 861151-12-4 98%
    Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder.
    Rosonabant
  • HY-14895
    Fabomotizole 173352-21-1 99.96%
    Fabomotizole (CM346) is an insecticide with anxiolytic, antianxiety, and neuroprotective activities and a substrate of p-glycoprotein. Fabomotizole inhibits the ST-segment depression induced by isoproterenol in a rat model of acute subendocardial ischemia. Fabomotizole also inhibits Giardia lamblia and has the potential to inhibit giardiasis. Fabomotizole also targets Sigma1R, NRH:quinone reductase 2 (NQO2), and MAO-A to exert anxiolytic effects.
    Fabomotizole
  • HY-15046
    EB-47 366454-36-6 98%
    EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. EB-47 mimics the substrate NAD+ and extends from the nicotinamide to the adenosine subsite.
    EB-47
  • HY-15406
    BNC105P 945771-96-0 98%
    BNC105P is a phosphate prodrug of BNC105 (HY-16114), that exhibits activity as a vascular disrupting agent (VDA) and an antitumor agent through conversion to active BNC105.
    BNC105P
  • HY-15692
    PHD2-IN-3 1000025-14-8 98%
    PHD2-IN-3 (compound 2) is a PHD2 inhibitor. PHD2-IN-3 can be used for study of anemia.
    PHD2-IN-3
  • HY-17447
    Tranylcypromine 155-09-9 98%
    Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.
    Tranylcypromine
  • HY-18211
    CGS 35601 849066-09-7 98%
    CGS 35601 is the inhibitor for endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), with IC50s of 55, 2, and 22 nM, respectively. CGS 35601 suppresses the big endothelin-1 (big ET-1)- and angiotensin I-induced pressor response, and enhances circulation of atrial natriuretic peptide (ANP), regulates the cardiovascular function in SD rats.
    CGS 35601
  • HY-18347
    Conivaptan 210101-16-9 98%
    Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function.
    Conivaptan
  • HY-19004
    711389-S hydrochloride 94899-83-9 98%
    711389-S hydrochloride is an antiarrhythmic compound that demonstrates its antiarrhythmic activity by increasing the ventricular fibrillation threshold (VFT). 711389-S hydrochloride also has strong anti-fibrillation effects and safety, and can be used in the study of ventricular fibrillation and sudden cardiac death.
    711389-S hydrochloride
  • HY-19012
    N-1518 93750-14-2 98%
    N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment.
    N-1518
  • HY-19053
    NP-252 132031-81-3 98%
    NP-252 is a calcium channel antagonist with an 20% effective dose (ED20) of 2.55 mg/kg in spontaneously hypertensive rats.
    NP-252
  • HY-19062
    SM-6586 103898-38-0 98%
    SM-6586 is a calcium channel antagonist and inhibitor of Na+/H+ and Na+/Ca2+ exchange transport, potentially for the treatment of cerebrovasular diseases and hypertension.
    SM-6586
  • HY-19063
    SCH-34826 105262-04-2 98%
    SCH-34826 is an orally active neutral metalloendopeptidase (NEP) inhibitor that inhibits NEP and reduces the degradation of ANF, thereby enhancing its antihypertensive and diuretic effects. SCH-34826 can be used in the research of cardiovascular and renal diseases.
    SCH-34826
  • HY-19097
    Ro-24-4736 125030-71-9 98%
    Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ro-24-4736
  • HY-19115
    YM-430 153192-22-4 98%
    YM-430 is an oral active calcium entry-blocking and beta-adrenoceptor-blocking agent. YM-430 inhibits Amifampridine (HY-14946)-induced rhythmic contractions with an IC50 value of 59.2 nM and inhibits arginine vasopressin-induced ST-segment depression with an IC50 value of 36.6 mg/kg. YM-430 can be used for study of angina pectoris.
    YM-430
  • HY-19121
    TCV-309 131311-25-6 98%
    TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function.
    TCV-309
  • HY-19163
    SC-52012 145643-15-8 98%
    HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.
    SC-52012
  • HY-19191
    L-159282 157263-00-8 98%
    L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.
    L-159282
  • HY-19210
    SB-209670 157659-79-5 98%
    SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty.
    SB-209670
Cat. No. Product Name / Synonyms Application Reactivity